Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: About four cases

AIDS

Volumn 23, Issue 7, 2009, Pages 869-871

  Ménard, Amélie ^a   Solas, Caroline ^b   Mokthari, Saadia ^c   Bregigeon, Sylvie ^a   Drogoul, Marie Pierre ^a   Tamalet, Catherine ^b   Lacarelle, Bruno ^b   Martin, Isabelle Poizot ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b TIMONE HOSPITAL   (France)

^c HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GLUCURONOSYLTRANSFERASE 1A1; RALTEGRAVIR; TENOFOVIR; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDAZINE DERIVATIVE;

ADULT; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; MALE; PRIORITY JOURNAL; VIRUS LOAD; DRUG INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY;

ANTI-HIV AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HIV-1; HUMANS; PYRIDAZINES; PYRROLIDINONES; VIRAL LOAD;

EID: 67649670094     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328329915f     Document Type: Letter

References (6)

1. Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008;52: 4228-4232.
2. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Synd 2006;43:509-515.
3. Iwamoto M, Wenning LA, Petry AS, Laethem M, DeSmet M, Kost JT, et al. Safety, tolerability and pharmokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83:293-299.
4. Rahal A, Soulie C, Schneider L, Ghosn J, Bouse F, Reynes J, et al. Therapeutic drug monitoring of raltegravir (MK-0518) in experienced HIV-infected patients. In: 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2008; New Orleans, LA. Oral presentation #O25.
5. Wenning L, Hwang E, Nguyen BY, Teppler H, Danovich R, Iwamoto M, et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses for raltegravir (RAL) in phase III studies in treatment experienced HIV-infected patients following 48 weeks of treat- ment.In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 28 October 2008; Washington, DC. Poster presentation #H-4054.
6. Kakuda TN, Scholler-Gyure M, Peeters M, Corbett C, De Smedt G, Woodfall BJ, et al. Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-I-infected subjects. In: 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2008; New Orleans, LA. Poster presentation #P34.